| Patient | Ida B. Wells |
|---|---|
| Date of birth | 1862-07-16 |
| Identifiers | MRN HR-ET022-SYN-TD; SSN (made up) 000-22-5903 |
| Document date | 1931-02-17 |
| Author | Cordelia Ashworth-Banks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit. [S]
Mrs. Wells comes for her subsequent annual wellness visit two weeks after starting dapagliflozin and four weeks after starting losartan for chronic kidney disease G3b A2 with hypertension. She has had no dizziness, faintness or genital itching and passes a little more urine than before. Her home blood pressure readings average 134/80. Her ankles no longer swell by evening, and she is less tired in the afternoons. Acetaminophen controls her knee aching and she has taken no naproxen since the first visit. Last week she went to the kidney education session at the health center, brought a page of questions, and asked to spend part of today on what the treatment options would mean for her if her kidneys failed one day. She has had no falls, emergency visits or hospital stays in the past year. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit, age 68 |
| New medicines | Losartan for four weeks and dapagliflozin for two, without side effects |
| Home blood pressure | Average 134/80 |
| Symptoms | Ankle swelling gone; less tired |
| Safety events | No falls, emergency visits or hospital stays |
Health risk assessment. Completed by her on paper before the visit and reviewed with her by Dr. Ashworth-Banks. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair; better than a month ago |
| Psychosocial | Lives with her husband; a wide circle of colleagues and readers; busy with writing and civic work; stress from deadlines is manageable |
| Behavioral | Never smoker; under one drink a week; walks most days; cutting salt with help from the dietitian; sleeps about six and a half hours |
| Activities of daily living | Independent in bathing, dressing, eating, toileting and transfers |
| Instrumental activities of daily living | Manages her own medicines, money, correspondence and travel |
| Home safety | Smoke detectors working; handrail on the front steps; no loose rugs |
| Hearing and vision | Hears well; reading glasses; last eye examination more than two years ago |
| Bladder | Passes a little more urine since dapagliflozin; no leakage |
| Memory | No concerns |
| Health care experiences | Wants to see the evidence and the numbers; says she was once told a kidney result was normal without anyone explaining how it was calculated |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tiredness in the afternoons, less than before; weight down 1.2 kg since intake |
| Eyes | Negative | No change in vision with reading glasses |
| Ears, nose, mouth, and throat | Negative | No hearing difficulty; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No nausea, poor appetite or blood in the stool |
| Genitourinary | Negative | No burning, genital itching or blood in the urine |
| Musculoskeletal | Positive | Knee aching on stairs, controlled with acetaminophen |
| Integumentary | Negative | No itching or rash |
| Neurological | Negative | No dizziness on standing, numbness or memory change |
| Psychiatric | Negative | Mood steady; PHQ-2 0 |
| Breast | Negative | No lump or nipple change |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen | One or two tablets up to three times a day as needed | Oral route | 1931-01-05 | active | S |
| Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 1931-01-20 to 1931-03-03 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1931-01-20 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily | One tablet daily | Oral route | 1931-01-20 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery | One tablet daily, with sick-day rules | Oral route | 1931-02-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1931-02-17 | Body height | 157 | cm | S |
| 1931-02-17 | Body weight | 69.2 | kg | S |
| 1931-02-17 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 1931-02-17 | Systolic blood pressure | 136 | mm[Hg] | S |
| 1931-02-17 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1931-02-17 | Heart rate | 72 | /min | S |
| 1931-02-17 | Respiratory rate | 16 | /min | S |
| 1931-02-17 | Body temperature | 36.6 | Cel | S |
| 1931-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1931-02-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1931-02-17 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1931-02-17 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 1931-02-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 69.2 kg; blood pressure 136/82 seated and 132/80 standing, without symptoms |
| Eyes | Near vision 20/30 with reading glasses; undilated fundi show mild arteriolar narrowing |
| Ears | Whispered-voice test passed in both ears |
| Neck | No thyroid enlargement or nodes; no carotid bruits |
| Cardiovascular | Regular rhythm; no murmur; no ankle swelling |
| Respiratory | Clear |
| Abdomen | Soft; no masses or bruits |
| Musculoskeletal | Crepitus in both knees without effusion; Timed Up and Go 11 seconds with a steady gait |
| Neurological | Oriented; Mini-Cog 5 of 5 (recall 3 of 3, clock normal) |
| Skin | No suspicious lesions |
| Psychiatric | Engaged, exact and well informed; judgment intact |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Tiredness for some months and ankle swelling by evening, with a raised creatinine (1.42 mg/dL, race-free eGFR 40, confirmed at 38 with cystatin C) and albumin in the urine (240 mg/g) found today; cause and chronicity to be established | resolved | confirmed | R94.4 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks. |
| Elevated blood pressure at intake (164/94 mmHg, average of two readings), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Hypertension, stage 2, confirmed by home readings (average 150/88 mmHg), with chronic kidney disease | active | confirmed | I12.9 | S — Synthetic modern diagnosis; no blood pressure from her life is recorded. |
| Chronic kidney disease G3b A2 (eGFR 38 by creatinine and cystatin C, urine albumin-to-creatinine ratio 240 and 228 mg/g), present at least two years; small, echogenic kidneys without obstruction; most likely hypertensive kidney disease, with APOL1-associated disease possible; 5-year kidney failure risk about 7% | active | confirmed | N18.32 | S — Synthetic modern diagnosis linked to the kidney disease recorded at her death. |
| Anemia of chronic kidney disease, mild (hemoglobin 11.2 g/dL) with adequate iron stores; a likely part of her tiredness | active | confirmed | D63.1 | S — Synthetic laboratory finding. |
| Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL) with a mildly raised PTH (84 pg/mL); calcium and phosphate normal | active | confirmed | E55.9 | S — Synthetic laboratory finding, part of the mineral and bone check in kidney disease. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening | Completed today | AUDIT-C score 1 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | No falls; Timed Up and Go 11 seconds; home safety reviewed |
| Breast cancer screening | Ordered | Mammogram every two years to 74; last one more than two years ago |
| Colorectal cancer screening | Ordered | Stool immunochemical test, her choice, to avoid bowel preparation fluids and sedation while her kidney medicines are new |
| Bone density (DXA) | Ordered | Women 65 and older; none on record; kidney disease adds to fracture risk |
| Hepatitis C and HIV screening | Up to date | Both negative with the kidney tests last month |
| Influenza vaccine, this season | Up to date | High-dose vaccine last month |
| Pneumococcal vaccine | Up to date | PCV20 last month; no further doses |
| Hepatitis B vaccine | Completed today | Dose 2 of HepB-CpG today; series complete; antibody check after the series because of kidney disease |
| RSV vaccine | Completed today | Single dose for an adult under 75 with chronic kidney disease |
| Recombinant zoster vaccine | Completed today | Dose 1 today; dose 2 in two to six months |
| COVID-19 vaccine, this season | Due | At the next visit, to space the vaccines at her request |
| Tetanus booster | Up to date | Tdap six years ago |
| Eye examination | Due | More than two years since the last; dilated examination for hypertensive retinal changes |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never smoker |
| Cervical cancer screening | Not indicated | Not recommended after 65 with adequate prior screening, which she reports |
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Respiratory syncytial virus vaccine, adjuvanted (RSVPreF3), single dose; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); Adult Immunization Schedule by Age (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Breast Cancer: Screening (2024); Colorectal Cancer: Screening (2021); Osteoporosis to Prevent Fractures: Screening (2025); Falls Prevention in Community-Dwelling Older Adults: Interventions (2024)
Follow-up: Review in two weeks with potassium and creatinine. Mammogram, bone density scan and stool test as ordered. Next annual wellness visit in one year. Next scheduled visit 1931-03-03: four weeks after starting dapagliflozin: potassium, creatinine and blood pressure, the losartan dose, and the plan for the months ahead. [S]
Voluntary advance care planning discussion of about 25 minutes, with her consent, building on the kidney education session. She understands that her kidney disease is at stage G3b and that, with treatment, most people at her stage do not reach kidney failure; the estimate of her own 5-year risk was explained as about 7 in 100. If her kidneys were to fail, she would want to be assessed for a transplant, would prefer home dialysis to center dialysis if dialysis were needed, and wants conservative kidney management explained to her again before any choice is made. She wants full treatment for illness that can be reversed. She has named a health care agent, recorded in the confidential part of the chart and not named here. To be revisited yearly, at any sustained fall in eGFR below 20, or after a serious illness. [S]